I-Mab (Nasdaq:IMAB) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

IMAB Aperçu des actions

I-Mab, société biopharmaceutique en phase clinique, découvre, développe et commercialise des produits biologiques dans les domaines de l'immuno-oncologie et des maladies immuno-inflammatoires, principalement aux États-Unis.

A propos de l'entreprise

IMAB analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 29.33% par an

Analyse des risques

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

N'a pas de revenus significatifs ( CN¥28M )

N'a pas de capitalisation boursière significative ( $97M )

I-Mab Concurrents

Verastem

NasdaqCM:VSTM

US$100.2m

Cibus

NasdaqCM:CBUS

US$196.9m

vTv Therapeutics

NasdaqCM:VTVT

US$46.7m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour I-Mab
Historique des cours de bourse
Prix actuel de l'action	US$1.20
Plus haut sur 52 semaines	US$2.54
Plus bas sur 52 semaines	US$0.99
Bêta	1.08
1Variation sur 1 mois	-16.08%
Variation sur 3 mois	-31.82%
Variation sur 1 an	-39.24%
3Variation sur 3 ans	-98.24%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-90.40%

Nouvelles et mises à jour récentes

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock

Jul 02

Rendement pour les actionnaires

	IMAB	US Biotechs	US Marché
7D	13.2%	3.5%	3.1%
1Y	-39.2%	14.9%	25.4%

Rendement vs Industrie: IMAB a sous-performé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: IMAB a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is IMAB's price volatile compared to industry and market?
IMAB volatility
IMAB Average Weekly Movement	9.2%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: Le cours de l'action de IMAB a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de IMAB ( 9% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2014	220	Sean Fu	ir.i-mabbiopharma.com

I-Mab, une société biopharmaceutique en phase clinique, découvre, développe et commercialise des produits biologiques dans les domaines de l'immuno-oncologie et des maladies immuno-inflammatoires, principalement aux États-Unis. Elle développe Uliledlimab, un anticorps neutralisant CD73, qui est en essai clinique de phase 2 pour le traitement des tumeurs solides ; Givastomig, un anticorps bi-spécifique qui est en essai clinique de phase 1 pour le traitement du cancer gastrique et d'autres cancers ; et Ragistomig, un engageur de cellules T dépendant des tumeurs et basé sur le ligand de la mort cellulaire programmée, qui est en essai clinique de phase 1 pour le traitement des tumeurs solides. La société évalue également les possibilités de développement du Lemzoparlimab, un anticorps monoclonal CD47 entièrement humain pour l'immunothérapie du cancer.

I-Mab Résumé des fondamentaux

Comment les bénéfices et les revenus de I-Mab se comparent-ils à sa capitalisation boursière ?
IMAB statistiques fondamentales
Capitalisation boursière	US$96.03m
Bénéfices(TTM)	-US$205.67m
Recettes(TTM)	US$3.88m

25.0x

Ratio P/S

-0.5x

Ratio P/E

Le site IMAB est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
IMAB compte de résultat (TTM)
Recettes	CN¥27.64m
Coût des recettes	CN¥0
Marge brute	CN¥27.64m
Autres dépenses	CN¥1.49b
Les revenus	-CN¥1.47b

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

Aug 28, 2024

Résultat par action (EPS)	-18.16
Marge brute	100.00%
Marge bénéficiaire nette	-5,302.03%
Ratio dettes/capitaux propres	1.7%

Quelles ont été les performances à long terme de IMAB?

Voir les performances historiques et les comparaisons

IMAB Aperçu des actions

Récompenses

Analyse des risques

I-Mab Concurrents

NasdaqCM:VSTM

US$100.2m

NasdaqCM:CBUS

US$196.9m

NasdaqCM:VTVT

US$46.7m

NasdaqGS:FIXX

US$54.3m

Historique des prix et performances

Nouvelles et mises à jour récentes

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab